Brad Glick, DO, FAAD: Dermatologic Signs of COVID-19


The dermatologist fields questions on possible symptoms and signs of infection that his colleagues have observed.

What is the dermatologist’s role during the coronavirus 2019 (COVID-19) pandemic? What procedures need to be prioritized? What relevant therapies are coming up in COVID-19 research?

These questions—and dozens more—were fielded during the HCPLive® and Dermatology Times free online webinar, “Derm Clinical Updates: Keeping Up with COVID-19,” on April 30. The hour-long webinar was led by a panel of 4 experts and clinicians, and covered as many relevant facets of dermatology as there could be in the current coronavirus discussion.

But it didn’t get to all of its audience’s questions.

In an interview with HCPLive, webinar moderator and board-certified dermatologist Brad Glick, DO, FAAD, of the Glick Skin Institute of Miami, FL, fielded a series of leftover questions pertaining to dermatologic manifestations of COVID-19 prosed by audience members on April 30.

Namely, Glick discussed persistent generalized urticaria, thromboembolic cutaneous changes, and “COVID toes.”

“We have seen some patients presenting with what we are learning more about are these ‘COVID rashes,’ and yet the symptom complex isn’t necessarily inclusive of all those common physical features, respiratory symptoms that we’re seeing in some patients,” he explained.

Related Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
© 2024 MJH Life Sciences

All rights reserved.